Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma
Year: 2015
Type: article
Study design: Clinical Trial
Source: Blood
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Leukemia and Lymphoma Society, Cutaneous Lymphoma Foundation, Adaptive Biotechnologies, Galderma, National Institutes of Health, U.S. Food and Drug Administration, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases
Awards: CTCL immunobiology: lessons from alemtuzumab, G4213117192, CD164 as a novel biomarker for malignant CD4 T cells in cutaneous T cell lymphoma, Toll Receptor Ligand Therapy of Cutaneous T-Cell Lymphoma, Transforming the diagnosis and care of patients with CTCL using TCR sequencing, Immune Evasion in Human Squamous Cell Carcinomas of the Skin, Vaccination to generate protective tissue resident T cells, Abramson Cancer Center Support Grant
OpenAlex ID: W2237699600
